Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, AMG 994, to see if it is safe and effective for treating advanced solid tumors. The trial will also test AMG 994 in combination with another drug, AMG 404, to see if the combination is more effective than AMG 994 alone.
- Advanced Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Part 2: Dose Expansion
- Group 2: Part 1b: Dose Exploration
- Group 3: Part 1c: Dose Exploration
- Group 4: Part 1a: Dose Exploration
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are responsible for overseeing the execution of this research trial?
"Patients are being recruited for this medical trial at the Princess Margaret Cancer Centre in Toronto, Sarah Cannon Research Institute in Nashville and Henry Ford Hospital/Henry Ford Health Systems in Detroit. Additionally, there are 5 other geographic locations involved."
Can I join this research project?
"This trial is enrolling 11 qualified participants, aged 18 - 100 years old, who have advanced solid tumours. Aside from this general criteria, prospective candidates must be willing to submit a biopsy before and during their treatment with AMG 994; they must also sign an informed consent document prior to any study-specific activities/procedures. Eligible cancers include mesothelioma, pancreatic adenocarcinoma, MSLN positive NSCLC squamous cell carcinoma or adenocarcinoma and high grade serous ovarian carcinomas that are measurable or evaluable as per modified RECIST 1"
Is AMG 994 dangerous to patients if administered correctly?
"The safety of AMG 994 is rated a 1 on the Power scale, due to this being an early-phase study with limited evidence related to its efficacy and security."
Does this research experiment permit persons over 30 to participate?
"In keeping with the conditions of participation in this medical trial, applicants must be no younger than 18 and not exceed 100 years old."
Are there any available slots for participants in this experiment?
"As per the clinicaltrials.gov portal, this trial is not currently accepting candidates; it was first posted on April 29th 2021 and most recently updated November 16th 2022. Nevertheless, there are presently 2502 other studies actively recruiting participants to join their trials."
Share this study with friends
Copy Link
Messenger